|
Reclaiming Our Prodigal Sons and Daughters.(Reclaiming Our Prodigal Sons and Daughters: A Practical Approach for Connecting with Youth in Conflict )(Brief article)(Book review)
Small Press Bookwatch
|
April 1, 2006
|
COPYRIGHT 2006 Midwest Book Review. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group.
(Hide copyright information)
Copyright
|
Reclaiming Our Prodigal Sons And Daughters
Scott Larson & Larry Brendtro
Solution Tree
1252 Loesch Rd, Bloomington, IN 47404
1879639696 $18.95 www.solution-tree.com
Deftly co-authored by Scott Larson (President and co-founder of Straight Ahead Ministries) and Larry K. Brendtro (President of Reclaiming Youth International), Reclaiming Our Prodigal Sons And Daughters: A Practical Approach For Connecting With Youth In Conflict is an excellent introduction and cogent exploration of ...
|
Isis Acquires Symphony GenIsis.
PR Newswire
; ISIS 301012 now under Isis' ownership in preparation for partnering CARLSBAD, Calif., Sept. 27 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. , today announced its purchase of all of the...
|
|
|
ISIS BEGINS PHASE III CLINICAL TRIALS OF ANTISENSE COMPOUND TO TREAT CMV RETINITIS IN PATIENTS WITH AIDS
PR Newswire
; ...Calif., Dec. 14 /PRNewswire/ -- Isis Pharmaceuticals (Nasdaq: ISIP) announced...controlled, Phase III clinical trials of ISIS 2922, an antisense compound to treat cytomegalovirus...and leads to blindness if not treated. ISIS 2922 is an antisense compound that inhibits...
|
|
|
ISIS PHARMACEUTICALS ANNOUNCES AGREEMENT WITH ZENECA LTD. FOR MANUFACTURE OF NOVEL ANTI-HIV COMPOUND
PR Newswire
; CARLSBAD, Calif., Nov. 16 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIP) announced...Biochemicals (CRB) business, for the manufacture of Isis' anti-HIV compound, ISIS 5320, a phosphorothioate oligonucleotide, eight...
|
|
|
ISIS 301012 Does Not Interact With Currently Marketed Lipid Lowering Drugs.
PR Newswire
; ...March 13 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. today announced additional data from clinical studies of ISIS 301012 that continue to broaden the potential...In a drug-drug interaction study, ISIS 301012 did not interact with simvastatin...
|
|
|
Isis to Proceed With Development of ISIS 3521 and ISIS 5132 as Novartis Concludes Participation.
PR Newswire
; CARLSBAD, Calif., Nov. 22 /PRNewswire/ -- Isis Pharmaceuticals (Nasdaq: ISIP) announced today that...will conclude its participation in the development of ISIS 3521 and ISIS 5132, two anticancer compounds, at the completion of...
|
|
|
ISIS 301012 Reduces Atherosclerotic Plaques in Animal Models.
PR Newswire
; Data Confirms That ISIS 301012 Has Potential to Benefit Patients With...April 27 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. today announced results of a study showing that ISIS 301012 reduced atherosclerotic plaques, apoB...
|
|
Isis Distributed Systems and IONA Technologies announces first shipment of Orbix + Isis; The first fault-tolerant object request broker.
Business Wire
; ...BUSINESS WIRE)--Aug. 14, 1995--Isis Distributed Systems Inc. and IONA Technologies...World, the commercial shipment of Orbix + Isis, the industry's first fault-tolerant Object Request Broker (ORB). Orbix + Isis, a joint development between Isis Distributed...
|
|
|
Isis Begins Phase I/II Trial of Second Generation CMV Retinitis Compound
PR Newswire
; ...Calif., Jan. 6 /PRNewswire/ -- Isis Pharmaceuticals (Nasdaq: ISIP) announced...beginning of Phase I/II clinical trials of ISIS 13312, a compound to treat cytomegalovirus...threatening infection in patients with AIDS. ISIS 13312 is the company's first compound...
|
|
|
Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes.
PR Newswire
; ...Oct. 18 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. today announced...SGLT2) to its development pipeline. ISIS 388626, a generation 2.2 antisense drug...increase glucose excretion, complements Isis' existing pipeline of drugs in development...
|
|
|
Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568.
PR Newswire
; ISIS 325568 is an Antisense Drug Targeting Glucagon...Oct. 2 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced today it...initializing the Phase 1 clinical trial of ISIS 325568. The collaboration between Isis and...
|
Find more facts and information related to the
article "Reclaiming Our Prodigal Sons and ..."
